Erin Slifer M.P.H.
Senior Vice President
Erin Slifer leads Impact Health’s Medicare Advantage and Part D portfolio, where she brings extensive expertise regarding prescription drug coverage, FDA approval, Medicare coverage and reimbursement, and other matters impacting a range of stakeholders in the space. Through her work with these clients, Erin often presents comprehensive landscape assessments on key, current health policy topics impacting their goals and has published articles on the Commonwealth Fund’s To the Point blog addressing drug pricing reform and pharmacy benefit manager reform under the Biden Administration.
Erin is also responsible for overseeing the firm’s state policy consulting capabilities, including State Policy Hub, a biweekly newsletter capturing state developments relevant to federal affairs professionals, state bill tracking, and in-depth analysis of state policy issues. Through these services, she ensures that clients are aware of variations and trends in state policies and can anticipate which among those may be considered at the federal level
Prior to joining Impact Health, Erin served as an intern for Congressman Dutch Ruppersberger, where she developed policy analysis experience. Additionally, Erin interned for xG Health Solutions and gained experience with key delivery reforms, including implementation of Affordable Care Act-driven accountable care organizations and bundled payment initiatives.
Erin holds an MPH from the University of Maryland and completed her capstone project with Wynne Health Group on legislative and regulatory developments affecting drug pricing from 2018 to 2019. Erin graduated from Princeton University in 2015 with a B.A. degree in politics. She currently lives in Alexandria, VA.
E&C FDA User Fee Reauthorization Package Addresses the Accelerated Approval Pathway, Clinical Trial Diversity, and Generic Market Entry
Yesterday, the House Energy and Commerce (E&C) Committee released the legislative text for the reauthorization of the Food and Drug Administration (FDA) user fee agreements, including the Prescription Drug User Fee Act (PDUFA), the Generic Drug User Fee Act (GDUFA), the Biosimilar User Fee Act (BsUFA), and the Medical Device User Fee Act (MDUFA) (press…
Senate HELP Hearing on FDA User Fees: Advancing Medical Product Regulation and Innovation for Benefits and Patients
On April 26, 2022, the Senate Committee on Health, Education, Labor, and Pensions (HELP) convened a hearing with the directors of the Food and Drug Administration (FDA) to discuss the reauthorization of the FDA user fee amendment programs. Directors from the FDA Centers discussed how the Prescription Drug User Fee Amendments (PDUFA), the Biosimilar User…
State of the Union Addresses Drug Pricing, COVID-19, Mental Health, and More
President Biden addressed Congress in his first State of the Union address. While most of his remarks were focused on the evolving situation in Ukraine and the economy, the President addressed several health care priorities including lingering provisions from the Build Back Better Act (BBBA), COVID-19, and mental health, among other topics. Additional details on health care priorities follow….
CMS Finalizes a Subset of Policies in MA and Part D Final Rule, Including ESRD MA Enrollment and MA and Part D Star Rating Changes; Subsequent Final Rule to Address Remaining Policies
On May 22, 2020, the Centers for Medicare & Medicaid Services (CMS) released the Contract Year (CY) 2021 Medicare Advantage (MA) and Part D Final Rule (press release; fact sheet). Â Of note, CMS is finalizing only a subset of the proposed policies, and will address the remaining proposed policies in subsequent rulemaking in 2020. What…
Ten Years Later: The ACA Now (Part III)
Note: This is the third in a three-part blog series highlighting the 10th anniversary of the Affordable Care Act (ACA) (see part I of the series here; and part II here). We invite you to visit ACA Now, the most comprehensive and user-friendly online resource summarizing key developments for every provision of the law over the…